Asset Details
Do you wish to reserve the book?
HER2陽性轉移性乳癌治療新希望－從護理的觀點談賀癌寧（trastuzumab emtansine）及其照護
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
HER2陽性轉移性乳癌治療新希望－從護理的觀點談賀癌寧（trastuzumab emtansine）及其照護
Do you wish to request the book?
HER2陽性轉移性乳癌治療新希望－從護理的觀點談賀癌寧（trastuzumab emtansine）及其照護
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
HER2陽性轉移性乳癌治療新希望－從護理的觀點談賀癌寧（trastuzumab emtansine）及其照護
2016
Overview
第二型人類上皮細胞生長因子接受器（human epidermal growth factor receptor, HER2）陽性的乳癌病患，具較嚴重的疾病及較差的預後。對抗HER2的標靶藥物－賀癌平（trastuzumab）的發展，使得HER2陽性乳癌的病患存活率顯著提升。然而，轉移性HER2陽性的乳癌最終都將會發展出抗藥性。近年來，新的抗體與化學治療複合（anti body-drug conjugate）的藥物－賀癌寧（trastuzumab emtansine, T-DM1），可以改善抗藥性乳癌的治療成效。賀癌寧可能會出現的副作用有：血小板減少、肝功能指數升高、疲憊、心臟功能的影響、肺炎及周邊神經病變等。護理師必須瞭解此藥物的作用機制及副作用、給藥注意事項、評估副作用及處理方法，以確保病患安全，提升照護能力及護理品質。
